Status: Not yet recruiting
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
This study is a Phase II single-arm, open label, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma .
Participants needed: 54
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Jin LiUpdated: Oct 13, 2023
Eligibility criteria
The patient voluntarily joined the study and signed the informed consent. [+8]
Previous (within 5 years) or concurrent with other uncured malignant tumors, exc... [+13]